Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial - Scorecard - MDSpire

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • By

  • Julio Rosenstock

  • Ildiko Lingvay

  • Donna Ryan

  • Ania M. Jastreboff

  • Robert Kushner

  • Andres Acosta

  • Thomas C. Blevins

  • Melissa Choi

  • Faith L. Holmes

  • Timothy Smith

  • Lisa Connery

  • Yao Li

  • Mike Ke Liu

  • Aline Barth

  • Jamie Butcher

  • Antonio Civitarese

  • Huibin Yue

  • Blai Coll

  • June 5, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy of the oral small molecule GLP-1 receptor agonist aleniglipron in individuals with overweight or obesity: results from a randomized, double-blind, placebo-controlled phase 2b study

At a Glance

CategoryDetail
Condition
Key MechanismsGLP-1 receptor agonism decreases appetite, increases satiety, and delays gastric emptying [source needed]
Target Population
Care Setting

Key Highlights

  • common_adverse_events

Guideline-Based Recommendations

Diagnosis

    Management

    • C
    • o
    • n
    • s
    • i
    • d
    • e
    • r
    • a
    • t
    • i
    • o
    • n
    • o
    • f
    • o
    • r
    • a
    • l
    • G
    • L
    • P
    • -
    • 1
    • r
    • e
    • c
    • e
    • p
    • t
    • o
    • r
    • a
    • g
    • o
    • n
    • i
    • s
    • t
    • s
    • l
    • i
    • k
    • e
    • a
    • l
    • e
    • n
    • i
    • g
    • l
    • i
    • p
    • r
    • o
    • n
    • f
    • o
    • r
    • w
    • e
    • i
    • g
    • h
    • t
    • m
    • a
    • n
    • a
    • g
    • e
    • m
    • e
    • n
    • t
    • [
    • s
    • o
    • u
    • r
    • c
    • e
    • n
    • e
    • e
    • d
    • e
    • d
    • ]

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with a mean age of 49.8 years and a mean BMI of 39.5 kg/m²

        Aleniglipron was administered once daily with titration over 36 weeks

        Clinical Best Practices

        • titration_schedule

        Related Resources & Content

        Original Source(s)

        Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

        • by Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert Kushner, Andres Acosta, Thomas C. Blevins, Melissa Choi, Faith L. Holmes, Timothy Smith, Lisa Connery, Yao Li, Mike Ke Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll

        • June 5, 2026

        Related Content

        Affordable GLP-1? When Digital Platforms Meet Policy Reform

        Side Effects: They Googled It

        Patients are mining Reddit and TikTok for symptom intel while you're not — and a small study calls it epistemic injustice. Different knowledge, mutually unrecognized. Maybe ask where they've been reading before you wave it off as anecdote.

        Lipidomics Point to Obesity–Alzheimer's Link

        Study uses multi-omics tools to examine obesity-related pathways linked to neurodegeneration

        • May 26, 2026

        • 2 min